<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441581</url>
  </required_header>
  <id_info>
    <org_study_id>3030-401-002</org_study_id>
    <nct_id>NCT03441581</nct_id>
  </id_info>
  <brief_title>3030-401-002 ELX BAM Study</brief_title>
  <official_title>3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the possibility of a differential effect of eluxadoline on altered
      bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) patients with and without
      evidence of Bile Acid Malabsorption (BAM).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">July 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average Bristol Stool Form Scale (BSFS) score over 4 weeks of treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in the stool consistency will be assessed using the Bristol Stool Form Scale (BSFS) on a range from 1 (Separate hard lumps like nuts) to 7 (Watery).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced clinically significant change in Laboratory Tests</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who experienced clinically significant change in Vital Signs</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Change from Baseline in General Physical Condition as Measured through General Physical Exam</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 4-week average of daily bowel movement frequency during the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in the number of bowel movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 4-week average of daily worst abdominal pain scores during the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline of the average daily worst abdominal pain score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 4-week average of daily bloating scores during the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline of the abdominal bloating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 4-week average of urgency-free days in a week during the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline of the number of daily urgent bowel movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with any fecal incontinence during the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The proportion of patients with fecal incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IBS-QOL score at the end of the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The IBS-QoL questionnaire will be completed by participants at the study site at Baseline prior to the administration of study drug, and Week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum 7αC4 levels at the end of the treatment period</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Fasting serum 7αC4 level will be measured Baseline and at Week 4 to determine whether any changes occurred following treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Plasma concentration</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin: Minimum Plasma Concentration</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau: Area under the plasma concentration-time curve during the dosing interval</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Cmax</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Half-Life</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL: Apparent clearance for eluxadoline</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V: Apparent volume of distribution for eluxadoline</measure>
    <time_frame>Week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBS-D participants with evidence of BAM treated with Eluxadoline 100 mg oral tablets twice daily (BID) with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBS-D participants without evidence of BAM treated with Eluxadoline 100 mg oral tablets BID with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eluxadoline</intervention_name>
    <description>Eluxadoline 100 mg oral tablets BID with food.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women aged 18 to 65 years inclusive with a diagnosis of IBS-D per Rome IV
             criteria.

          -  Participants with evidence of BAM must have a fasting serum
             7a-hydroxy-4-cholesten-3-one (7αC4) level ≥ 52.5 ng/mL or total fecal bile acid (BA) &gt;
             2337 micromoles/48 hours (positive result) at screening or within 1 calendar year
             prior to screening.

          -  Participants without BAM must have a fasting serum 7αC4 level ≤ 47.1 ng/mL or total
             fecal BA &lt; 2200 micromoles/48 hours (negative result) at screening or within 1
             calendar year prior to screening.

          -  Has an average daily Bristol Stool Form Scale (BSFS) score ≥ 5.0 or ≥ 25% of diary
             entry days with a BSFS score of 6 or 7 during the 14 days prior to Day 1.

          -  Women of childbearing potential must use hormonal or double barrier contraception or
             maintain a monogamous relationship with a vasectomized male partner from the date of
             informed consent until 24 hours after final dose of study drug.

          -  Completed the electronic diary (eDiary) on ≥ 10 of the 14 days prior to Day 1.

          -  Has not used loperamide rescue medication on &gt; 3 of the 14 days prior to Day 1.

        Exclusion Criteria:

          -  Has a diagnosis of IBS with a subtype of irritable bowel syndrome with constipation
             (IBS-C), mixed IBS, or unsubtyped IBS per Rome IV criteria.

          -  Does not have a gallbladder.

          -  Has known or suspected biliary duct obstruction, or sphincter of Oddi disease or
             dysfunction. (Participants with a history of gallstones may be enrolled).

          -  Has a history of alcoholism, alcohol abuse or alcohol addiction, or drinks more than 3
             alcoholic beverages per day.

          -  Has a history of pancreatitis; structural diseases of the pancreas, including known or
             suspected pancreatic duct obstruction.

          -  Has a history of mild, moderate, or severe hepatic impairment according to Child-Pugh
             classification. History or current diagnosis of inflammatory or immune-mediated
             gastrointestinal (GI) disorders.

          -  Has Celiac disease or a positive serological test for celiac disease.

          -  Has known lactose or fructose intolerance associated with diarrhea, abdominal pain or
             discomfort, that could confound assessments in the study.

          -  Women who are currently pregnant or nursing, or plan to become pregnant or nurse
             during the study.

          -  Has known allergies or hypersensitivity to opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Muslin</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877‐277‐8566</phone>
    <email>IR‐CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR‐CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBS-D</keyword>
  <keyword>BAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

